NICE rejects breakthrough eczema jab on grounds of cost

A drug hailed as a “step change” in the treatment of chronic eczema has initially failed to win approval from the National Institute for Health and Care Excellence due to concerns about cost.
Source: Nursing Times - Category: Nursing Source Type: news